NewAmsterdam Pharma Company N.V. Ordinary Shares NAMS
Analyst Ratings
- Consensus
- Buy — 6 Buy · 1 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $47.43 (+110.0% upside)
Key Stats
- Today's Range
- $22.35 – $22.96
- 50-Day Range
- $21.02 – $32.63
- 52-Week Range
- $21.02 – $42.20
- Volume
- 1.14 million shs
- Average Volume
- 1.52 million shs
- Market Cap
- $2.70 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.27
- Price / Sales
- 379.04
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $7.12 million
- Net Income
- $-259,504,000
- Net Margin
- -3644.21%
- Return on Equity
- -41.10%
- Debt-to-Equity
- —
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Related Stocks
Compare head-to-head: NAMS vs LLY·NAMS vs JNJ·NAMS vs ABBV·NAMS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.